PI3K Inhibitors: Understanding Toxicity Mechanisms and Management
Here, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
SUBSCRIBE: Print / eNewsletter
Here, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.
While the headliners for the 2015 ASCO Annual Meeting featured mainly immunologic approaches to cancer treatment, with agents such as nivolumab and ipilimumab, the new data in hematologic malignancies highlighted a large number of novel therapies, each of which appears promising.
The number of recently approved agents and those under investigation is promising. However, there are currently no recommendations regarding the optimal timing for use of these agents, a reflection of the lack of data in this area and the need for prospective studies.